Wales Patient Access Scheme (WPAS)
The Wales Patient Access Scheme (WPAS) is a method used in Wales to allow NHS patients access to medicines that might otherwise be considered too expensive. It works by negotiating confidential discounts or rebates with drug manufacturers, making the medicines cost-effective for NHS Wales. The savings from these arrangements are reinvested into the health system.
At a glance
Use when
Evaluating reimbursement for medicines that exceed standard cost-effectiveness thresholds in Wales; when budget impact is a barrier to adoption; when confidential pricing can improve value for money
Avoid when
Full price transparency is required; when non-confidential pricing models are preferred; when the medicine is already cost-effective at list price
Inputs
Medicine cost, expected usage volume, list price, health technology assessment outcomes, budget impact projections
Outputs
Confidential discount rate, net cost to NHS Wales, patient access agreement, reinvestment plan for recouped savings
How it works
WPAS is a managed access mechanism administered by the All Wales Therapeutics and Toxicology Centre (AWTTC) on behalf of the Welsh Medicines Strategy Group (AWMSG). It facilitates reimbursement of medicines that do not meet standard cost-effectiveness thresholds by implementing confidential price reductions or rebates. These financial arrangements ensure budget neutrality for NHS Wales, with recouped savings used to support broader medicine access. The scheme operates within a formal governance framework and is specific to the Welsh healthcare context.
- HTA domains
- Costs & Economic Evaluation
- Categories
- Pricing/Payer
- Assumptions
- The manufacturer is willing to offer a confidential rebate; the medicine provides clinical benefit justifying access despite high list price; the financial arrangement maintains budget neutrality for NHS Wales
- Strengths
- Enables patient access to innovative or high-cost therapies; maintains cost control through rebates; reinvests savings into the health system; supports managed entry of medicines with uncertain evidence
- Limitations
- Lack of transparency due to confidentiality of discounts; potential inequity compared to other UK nations; reliance on manufacturer cooperation; limited public scrutiny of value assessments
- Also known as
- WPAS
Questions this answers
- › How can high-cost medicines be made available within NHS Wales despite exceeding standard cost-effectiveness thresholds?
- › How are budget impacts managed when funding medicines with uncertain long-term value?
- › What mechanisms enable equitable access to innovative therapies in a constrained budget environment?
References & sources
- websiteawttc.nhs.wales ↗
Similar by meaning
Beta record. Based on the original catalogue summary; primary-source enrichment pending.